WASHINGTON — Lawmakers have requested data and documents from the Food and Drug Administration related to the agency’s controversial accelerated approval of Biogen’s new Alzheimer’s drug, Aduhelm.
Two prominent House committees sent the request to acting FDA Commissioner Janet Woodcock on Wednesday. The same panels have already requested documents from Biogen, but this is the first public request by congressional investigators directly to the agency.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
